|

Avapritinib, azacitidine, Venetoclax Clinical Trials

1 actively recruiting trial

Pipeline

Phase 2: 1

Top Sponsors

  • Institute of Hematology & Blood Diseases Hospital, China1

Indications

  • AML (Acute Myelogenous Leukemia)1
  • Cancer1

Other1 trial

Avapritinib Combined With Azacitidine and Venetoclax in the Treatment of Relapsed AML After Allo-HSCT
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.